Latest Deals

The foundation is calling on philanthropists, governments, investors and the private sector to invest in women’s health innovations. Credit: Wright Studio / Shutterstock

The Gates Foundation has announced an investment of $2.5bn through to 2030, dedicated to expediting research and development (R&D) with a focus on improving women’s health globally. This initiative will support the advancement of more than 40 innovations targeting five critical and chronically underfunded areas, particularly affecting women in low and middle-income nations.

Fosun Pharma’s subsidiary, Fosun Pharma Industrial, has entered a licence agreement to grant ex-China rights for its experimental respiratory drug, XH-S004, to Expedition Therapeutics. This agreement grants US-based Expedition the rights to independently develop, manufacture and commercialise XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor developed by Fosun Pharma.

Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own.

CorMedix, a biopharmaceutical company specialising in critical care products, has signed an agreement to acquire Melinta Therapeutics for $300m upfront. The acquisition includes additional milestone payments related to the Food and Drug Administration (FDA) approval for the expanded Rezzayo indication. The total consideration will comprise $260m in cash and $40m in equity, which will be issued to Melinta’s shareholders of Deerfield Management Company.